Download MendeleyDiscovery ofN-(1-Acryloylazetidin-3-yl)-2-(1H-indol-1-yl)acetamides as Covalent Inhibitors of KRASG12C.
Shin, Y., Jeong, J.W., Wurz, R.P., Achanta, P., Arvedson, T., Bartberger, M.D., Campuzano, I.D.G., Fucini, R., Hansen, S.K., Ingersoll, J., Iwig, J.S., Lipford, J.R., Ma, V., Kopecky, D.J., McCarter, J., San Miguel, T., Mohr, C., Sabet, S., Saiki, A.Y., Sawayama, A., Sethofer, S., Tegley, C.M., Volak, L.P., Yang, K., Lanman, B.A., Erlanson, D.A., Cee, V.J.(2019) ACS Med Chem Lett 10: 1302-1308
- PubMed: 31531201
- DOI: https://doi.org/10.1021/acsmedchemlett.9b00258
- Primary Citation of Related Structures:
6P8W, 6P8X, 6P8Y, 6P8Z - PubMed Abstract:
KRAS regulates many cellular processes including proliferation, survival, and differentiation. Point mutants of KRAS have long been known to be molecular drivers of cancer. KRAS p.G12C , which occurs in approximately 14% of lung adenocarcinomas, 3-5% of colorectal cancers, and low levels in other solid tumors, represents an attractive therapeutic target for covalent inhibitors. Herein, we disclose the discovery of a class of novel, potent, and selective covalent inhibitors of KRAS G12C identified through a custom library synthesis and screening platform called Chemotype Evolution and structure-based design. Identification of a hidden surface groove bordered by H95/Y96/Q99 side chains was key to the optimization of this class of molecules. Best-in-series exemplars exhibit a rapid covalent reaction with cysteine 12 of GDP-KRAS G12C with submicromolar inhibition of downstream signaling in a KRAS G12C -specific manner.
Organizational Affiliation:
Departments of Therapeutic Discovery, Oncology Research, Pharmacokinetics and Drug Metabolism, Amgen Research, Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320, United States.
